Rep. Daniel S. Goldman sold Sarepta Therapeutics (SRPT)
Rep. Daniel S. Goldman (D-NY-10) · $1K–$15K · traded Jan 31, 2023
- Transaction
- Sold
- Amount
- $1K–$15K
- Owner
- Not stated
- Traded
- Jan 31, 2023
- Disclosed
- Feb 24, 2023
- Days to disclose
- 24
- Asset type
- Stock
- As filed
- Sarepta Therapeutics, Inc.
- Industry
- Biotechnology · Healthcare
Other trades in this filing
All of Goldman's trades →- Feb 24, 2023$1K–$15K
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$1K–$15K
Sold (partial) Wheaton Precious Metals WPM
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$1K–$15K
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$1K–$15K
Bought Verizon Communications VZ
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
Got $1K from the company’s PAC - Feb 24, 2023$50K–$100K
- Feb 24, 2023$15K–$50K
Sold (partial) UnitedHealth Group UNH
$15K–$50K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$1K–$15K
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$1K–$15K
Bought United Airlines Holdings UAL
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$50K–$100K
Sold (partial) Union Pacific UNP
$50K–$100K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$1K–$15K
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$15K–$50K
$15K–$50K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$100K–$250K
$100K–$250K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$1K–$15K
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$1K–$15K
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$1K–$15K
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$1K–$15K
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$1K–$15K
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$1K–$15K
Sold (partial) ShockWave Medical SWAV
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$15K–$50K
Bought The Sherwin-Williams Company SHW
$15K–$50K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 24, 2023$15K–$50K
Sold Seacoast Banking Corporation of Florida SBCF
$15K–$50K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
Recent Congress trades in SRPT
- May 6, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Sold Sarepta Therapeutics SRPT
$1K–$15K · Traded Apr 14, 2025 · disclosed May 6, 2025
- Aug 21, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Bought Sarepta Therapeutics SRPT
$1K–$15K · Traded Jul 14, 2023 · disclosed Aug 21, 2023 · Joint
- Jul 11, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold Sarepta Therapeutics SRPT
$1K–$15K · Traded Jun 13, 2023 · disclosed Jul 11, 2023 · Joint
- May 19, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Sold Sarepta Therapeutics SRPT
$15K–$50K · Traded Apr 10, 2023 · disclosed May 19, 2023
- Apr 20, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Bought Sarepta Therapeutics SRPT
$1K–$15K · Traded Mar 6, 2023 · disclosed Apr 20, 2023 · Joint
- Apr 17, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Bought Sarepta Therapeutics SRPT
$15K–$50K · Traded Mar 6, 2023 · disclosed Apr 17, 2023
Company context for SRPT
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
SRPT: third_quarter 2026 lobbying report
H.R. 9260 - LHHS Appropriations Rare Pediatric Disease Priority Review Voucher (PRV) Program Issues related to patient access to treatment National Security Commission on emerging biotechnology policy proposals Issues related to Section 232
Public: Oct 19, 2026, 4:58 PM EDTOriginal source ↗SRPT: second_quarter 2026 lobbying report
H.R. 9260 - LHHS Appropriations H.R. 1509 - Accelerating Kids Access to Care Act Patient Access Act Issues related to patient access to treatment National Security Commission on emerging biotechnology policy proposals Issues related to supply chain Issues related to Section 232
Public: Jul 20, 2026, 1:40 PM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.